NovaBridge to Present March 11 at Leerink Conference, Highlights Phase 2 Trials for Givastomig and VIS-101
NovaBridge will present at the Leerink Global Healthcare Conference on March 11 with a webcast accessible for 90 days, offering investors management insights. Its lead asset givastomig is entering a Phase 2 trial after positive Phase 1b gastric cancer topline results, and VIS-101 starts a dose-ranging Phase 2a study.
1. Conference Presentation
NovaBridge management will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11 at 8:00 AM ET. The live webcast will be available on the company website for 90 days, allowing investors to hear strategic updates and clinical progress directly from leadership.
2. Givastomig Progress
NovaBridge’s lead bispecific antibody, givastomig, targets Claudin 18.2 and 4-1BB, aiming to activate T cells in Claudin 18.2-positive tumors. Following positive topline data from a Phase 1b gastric cancer study, givastomig has advanced into a global Phase 2 trial evaluating efficacy in first-line gastric and other gastrointestinal malignancies.
3. VIS-101 Development
VIS-101, a bifunctional biologic addressing VEGF-A and ANG-2 pathways for wet age-related macular degeneration and diabetic macular edema, is in a randomized dose-ranging Phase 2a study. NovaBridge holds a majority stake in Visara, which controls global rights to VIS-101 outside Greater China and select Asian markets.